PALO ALTO, Calif. — Countable Labs, developer of Countable PCR, the leading innovation redefining how science measures biology, announced the launch of the RNA Module for Countable PCR. The new solution introduces direct counting of RNA, enabling one-step, bias-free RNA quantification and providing the simplicity, accuracy, and low variability essential for translational research, biopharma, and diagnostic applications. The company will also present new data at the Association for Molecular Pathology Annual Meeting and Expo, taking place November 11–15, 2025, in Boston, Massachusetts.
Countable PCR is a scalable technology leveraging single-molecule isolation across 30 million compartments per experiment to achieve true single-molecule quantification within a simple PCR workflow. Offering at least tenfold greater sensitivity and precision than other PCR technologies, Countable PCR allows the identification of rare events at variant allele frequencies as low as 0.004%, even from small sample inputs.
The RNA Module enhances workflow efficiency by eliminating the need for cDNA generation prior to PCR, allowing users to load RNA directly for one-step reverse transcription and amplification. This enables accurate RNA quantification with reduced variability and supports rapid detection of fusion transcripts, pathogens, RNA viral load, minimal residual disease (MRD), and other RNA molecules of interest. Unlike conventional PCR-based RNA methods, Countable PCR with the RNA Module delivers absolute RNA quantification across a dynamic range of 1 to 1 million target molecules per reaction, with sensitivity for viral RNA down to 0.001% and minimal variability.
“Our team has transformed the capabilities of legacy PCR techniques by developing Countable PCR to have superior performance, the highest multiplexing available, and a level of simplicity that addresses the shortcomings of qPCR, digital PCR, and even next-generation sequencing,” said Giovanna Prout, CEO of Countable Labs. “DNA and RNA applications are just the beginning of Countable Labs’ story. We are focused on building a robust product portfolio of multiomics and assays to support a broad range of clinical, translational, and research customers.”
To further support customers, Countable Labs launched a new Community Assays portal, providing access to pre-designed and pre-verified assays for diverse applications. The resource aims to accelerate adoption of Countable PCR and foster community-driven collaboration and innovation among researchers.
“There is a broad range of high-value applications for PCR-based RNA testing in areas where other PCR approaches are insufficiently specific or where next-generation sequencing is impractical or cost-prohibitive,” said Eleen Shum, Vice President of Product and Founding Scientist at Countable Labs. “Our direct counting approach simplifies accurate quantification and delivers a cost-effective solution for applications such as lentivirus quality control in cell and gene therapy manufacturing and minimal residual disease detection in cancer research.”
